Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287030 | 0.72 | JAK2 (0.35) | KMT2AALDH1A1L3MBTL1LMNA | |
| SCHEMBL7756991 | 0.63 | — | — | |
| SCHEMBL21469685 | 0.63 | KMT2A (0.41) | KMT2ATSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL29285117 | 0.62 | POLB (0.36) | KMT2A | |
| SCHEMBL22955528 | 0.62 | ALDH1A1 (0.41) | KMT2AALOX15TSHRALDH1A1L3MBTL1 | |
| SCHEMBL14212551 | 0.62 | ALDH1A1 (0.41) | KMT2ATSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL17110194 | 0.61 | KMT2A (0.41) | KMT2ATSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL1812258 | 0.61 | ALDH1A1 (0.43) | KMT2ATSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL20813 | 0.61 | ALDH1A1 (0.43) | KMT2ATSHRALDH1A1LMNACYP2C19 | |
| SCHEMBL22510982 | 0.61 | ALDH1A1 (0.41) | KMT2ATSHRALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | MYLK2, MYLK, MYLK3 | KMT2A 2307/4885ALOX15 3789/4885TSHR 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.